论文部分内容阅读
目的 观察患者服用甲孕酮后改善化疗所致的厌食、体重下降、ECOG下降、骨髓抑制及胃肠道反应的作用及止痛和促进蛋白同化作用。方法 130例接受化疗的晚期肺癌患者 ,分成单用化疗组及化疗 +甲孕酮组。结果 在化疗 +甲孕酮组治疗的 160个周期中有 4 3.1%食量增加 ;4 5%体重增长 ,平均每周期体重增加 0 .74± 1.56kg;血浆白蛋白升高 1.2± 2 .9g/ L、88.1%疼痛减轻及 2 8.1% ECOG改善。化疗的毒副作用 ,出现 度以上的白细胞下降占 33.8%、血红蛋白下降占 15.6%及胃肠道反应占 18.1%。结论 甲孕酮如能正确合理地用于晚期癌症的治疗 ,可以全面改善化疗期癌症患者的生活质量。
Objective To observe the effects of anorexia, weight loss, ECOG reduction, myelosuppression, and gastrointestinal tract reaction caused by chemotherapy in patients receiving medroxyprogesterone acetate, and to relieve pain and promote protein assimilation. Methods 130 patients with advanced lung cancer undergoing chemotherapy were divided into chemotherapy alone group and chemotherapy plus medroxyprogesterone group. Results 4 3.1% of the 160 cycles in the chemotherapy + medroxyprogesterone group had an increase in food intake; 45% of body weight gained, an average of 0.74±1.56kg per cycle of body weight gain; plasma albumin increased 1.2±2.9g L, 88.1% pain relief and 28.1% ECOG improvement. With toxic side effects of chemotherapy, 33.8% of leukocytopenia occurred, 15.6% of hemoglobin decreased, and 18.1% of gastrointestinal reactions occurred. Conclusion If medroxyprogesterone is used correctly and reasonably in the treatment of advanced cancer, it can improve the quality of life of cancer patients during chemotherapy.